Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review.

Age-related macular degeneration is the leading cause of vision loss in the developed world, with the expected number of affected elderly individuals reaching 17.8 million. Antivascular endothelial growth factor (anti-VEGF) injection therapy has been instrumental in treating a disease process that was previously thought to be untreatable. Over the past two decades, landmark studies have demonstrated the efficacy of different anti-VEGF medications and investigated the optimal dosing regimen and delivery mechanism to increase overall vision and minimise patient burden. In this review, we outline landmark neovascular age-related macular degeneration clinical trials that have demonstrated level 1 evidence for its usage or have contributed to the understanding of how to dose these agents.

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: SMH is a consultant or on speaker’s bureau for the following companies: Novartis/Alcon, Spark, Regeneron, Alimera Sciences, Clearside Biomedical, EyePoint Pharmaceuticals, OD-OS and Allergan. DAE is a speaker (S), consultant (C), investigator (I) or equity/stockholder (E) in the following companies: Genentech (C, I, S), Regeneron (C), Allergan (C, I, S), Clearside (C, I, E), Novartis (C, I, S), Alimera (C, I), Ophthotech (I), Opthea (I), US Retina (E), Hemera Biopharmaceuticals (E), Boston Image Reading Center (E), Notal Vision (C, S), Allegro (C), EyePoint (C), Mylan (I), Chengdu (I), Orbit Biomedical (C), Adverum (C) and Kodiak (C, I). TAC has an employment relationship with, and equity ownership in, Clearside Biomedical. This work was undertaken in his role as Volunteer Clinical Professor at the Indiana University School of Medicine.